Edwards Lifesciences Corporation, a prominent player in the field of medical systems and devices for cardiovascular disease treatment, has been given a neutral rating by UBS.

The company's sales are primarily driven by heart valves and cardiac surgery products, which account for 67.9% of total sales. Hemodynamic monitoring systems contribute 15.5%, while other products such as balloon catheters and artificial implants make up 16.6% of sales.

In terms of geographical distribution, the United States represents 58.4% of sales, followed by Europe at 22.2%, Japan at 7.6%, and other regions at 11.8%. This diverse product and geographical portfolio strategically positions Edwards Lifesciences within the healthcare market, allowing them to cater to a wide range of cardiovascular needs.